Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
- Our Priorities
- Pamrevlumab Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

November 6, 2023
FibroGen Reports Third Quarter 2023 Financial Results
October 23, 2023
FibroGen to Report Third Quarter 2023 Financial Results
August 29, 2023
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
August 7, 2023
FibroGen Reports Second Quarter 2023 Financial Results
July 25, 2023
FibroGen Announces Leadership Transition
July 24, 2023
FibroGen to Report Second Quarter 2023 Financial Results
June 26, 2023
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
June 7, 2023
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
June 6, 2023
FibroGen to Present at Upcoming Investor Conferences
May 18, 2023
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
May 8, 2023
FibroGen Reports First Quarter 2023 Financial Results
May 8, 2023
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
May 5, 2023
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
May 1, 2023
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
April 24, 2023
FibroGen to Report First Quarter 2023 Financial Results
April 3, 2023
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
February 27, 2023
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
February 17, 2023
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 2, 2023
FibroGen to Present at SVB Securities Global Biopharma Conference

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

Investors:
David DeLucia, CFA
Vice President, Corporate FP&A and Investor Relations
ir@fibrogen.com
Media Inquiries:
Meichiel Jennifer Keenan
Investor Relations & Corporate Communications
media@fibrogen.com

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
ESG
Medical Information
Contact Us

Focus Areas

Our Expertise
Anemia
Pancreatic Cancer
Duchenne Muscular Dystrophy
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Notice

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2023 FibroGen, Inc.
409 Illinois Street, San Francisco, CA 94158